DuPont AmberChrom SIL adds reverse phase silica to peptide purification lines

Chemical supplier DuPont has added a silica medium to its peptide purification range. The new DuPont AmberChrom SIL silica gel, announced on October 22, 2026 from Wilmington, Delaware, is a reverse phase material aimed at GLP 1 drugs and other peptide ingredients. It comes in two chemistries and can sit in the same process train as the company's polymer resins. DuPont gave no price, plant or tonnage.

What DuPont launched and what it left out

According to the company release, the product is a reverse phase, silica based medium sold in C8 and C18 versions. DuPont says it can be used for the first cleanup of crude peptide and for the final high purity polishing step, and at several stages in between. The release cites application studies showing what the company calls competitive purity and yield, with stable performance under conditions commonly used in peptide work, plus better results when the silica is paired with its AmberChrom XT resin. DuPont did not publish those studies, so the figures behind the claim are not available to check. The launch sits inside DuPont Water Solutions, the unit that already sells the AmberChrom polymer line to drug makers.

Several facts a buyer would want are missing from the announcement. DuPont did not give particle size, pore size or column loading data, did not say where the silica is made, and did not name any customer that has adopted it in a commercial process. It also gave no shipping date by region and no price. What it did give is positioning: the release frames DuPont AmberChrom SIL as a way to run silica and polymer media in a single workflow from one supplier. Hadi Fares, a bioprocessing application scientist at DuPont Water Solutions, said that "every peptide purification challenge is different" and that the company wants to help customers build workflows around their own purity targets.

Why reverse phase chromatography sets peptide cost

Most peptide ingredients leave synthesis as a crude mix. Alongside the target chain sit shorter sequences where a coupling failed, chains with a damaged residue and other close relatives that differ by only one building block. Reverse phase chromatography separates these by how strongly they stick to a water repelling surface, and the alkyl chains bonded to the silica set that strength. A C18 surface carries longer chains and usually holds peptides more tightly than C8, so the choice depends on how greasy the molecule is. Because the impurities can be nearly identical to the product, this step often decides final purity, and each extra pass through a column costs solvent, time and lost product.

DuPont did not publish those studies, so the figures behind the claim are not available to check.

Purification is also where much of the waste in peptide manufacturing ends up. Columns are run with large volumes of water and organic solvent, and those volumes grow with every gram of product. An industry group estimate put the usual method at around 13,000 kg of input for each kilogram of finished peptide, and chromatography is one of the larger contributors to that figure. Any medium that holds more product per run, survives more cleaning cycles or cuts the number of passes can lower that load. DuPont makes no number based claim of this kind in its release, so the effect of the new silica on solvent use is not yet known.

Silica and polymer in one purification train

DuPont already sells polymer based media under the same brand, and the release names three of them that can be combined with the silica: AmberChrom XT, AmberChrom TQ1 and AmberChrom CG. Polymer beads and bonded silica behave differently. Polymer media generally tolerate a wider pH range and harsher cleaning, while silica is prized for sharp separations in polishing steps. A common approach in industry is to run a robust capture or first pass column and then finish on a high resolution column. DuPont's pitch is that a manufacturer can now source both kinds of media from one catalogue and design those steps together, which may simplify supplier qualification for a new GLP 1 purification process.

The supplier also points to its history. DuPont says it has more than 80 years of experience with adsorbents and ion exchange resins, the chemistry that underlies its polymer media. That history is in polymers rather than in bonded silica, which makes DuPont AmberChrom SIL a new category for the brand. The release does not say whether DuPont makes the silica base itself or sources it and bonds it. For a drug maker, that matters because a change of media in a licensed process usually needs comparability work and regulatory filings, so media suppliers are often chosen early, during process development, and kept for years. The company says the product supports both development and scale up.

Where the launch fits in GLP 1 supply

DuPont ties the launch to demand for peptide drugs in diabetes and obesity and to newer uses in cancer. The firms that make GLP 1 ingredients run two broad routes. One route ferments part of the chain in yeast and completes it with chemical steps, as with semaglutide, while the other assembles the whole molecule on resin, as with tirzepatide, a split our explainer on the two ways GLP 1 peptides covers in detail. Both routes end in chromatographic cleanup before the ingredient can be released. That shared step is why media suppliers see GLP 1 volume as a market for columns and resins, separate from the market for synthesis reactors or fermentation tanks, which is where new plant money usually goes.

What the release cannot show is uptake. Media in a commercial process are locked in by validation, so a new silica is most likely to appear first in development programmes and new plants rather than in licensed lines already running. DuPont gave no customer names, no volume commitment and no manufacturing site for the product, so there is no capacity figure to add to the site plate. The DuPont release is the only public account so far. Independent data on loading, lifetime and solvent use would be needed before anyone can say how it compares with silica media already in use.

Conclusion

DuPont AmberChrom SIL gives DuPont a reverse phase silica to sell next to its polymer resins, in C8 and C18 versions aimed at peptide cleanup and polishing. The launch is a process tool, not new capacity: no plant, tonnage, price or customer was disclosed, and the performance studies cited have not been published. Whether peptide makers adopt it will show first in new GLP 1 processes still in development.